Exacerbations needing hospitalisation · Studies recruited adults and adolescents aged 12 and older with chronic asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations requiring oral corticosteroids ‐ adults · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief leads to lower patients with exacerbations requiring oral steroids compared with higher‐dose ICS/LABA + SABA (high certainty).
1 finding from 1 review
OR 0.75 [0.65, 0.87]
9096 participants
High
Patients with serious adverse events · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief showed no clear difference in patients with serious adverse events compared with higher‐dose ICS/LABA + SABA (moderate certainty).
1 finding from 1 review
OR 0.92 [0.74, 1.13]
9130 participants
Moderate
Patients with severe exacerbations (requiring hospitalisation or ER visit) · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief leads to lower patients with severe exacerbations (requiring hospitalisation or ER… compared with higher‐dose ICS/LABA + SABA (high certainty).
1 finding from 1 review
OR 0.72 [0.57, 0.9]
7768 participants
High
Number of participants experiencing one or more episode requiring treatment with oral steroids · children with asthma
Anti‐leukotrienes & ICS may leads to lower participants with one or more exacerbations requiring oral… compared with higher dose ICS (low certainty).
1 finding from 1 review
Hospital admissions due to exacerbations: number of participants · children with asthma
Anti‐leukotrienes & ICS may leads to higher participants with exacerbations requiring hospital admission compared with higher dose ICS (low certainty).
1 finding from 1 review
Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in bleeding: Numbers of patients with at least one significant bleeding… compared with higher transfusion threshold (20,000 or 30,000) (moderate certainty).
1 finding from 1 review
Mortality: secondary to bleeding · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in mortality: secondary to bleeding compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Underweight · healthy, full‐term (37 to 42 weeks), formula‐fed infants
1 finding from 1 review
Wasting · healthy, full‐term (37 to 42 weeks), formula‐fed infants
1 finding from 1 review
Overweight · healthy, full‐term (37 to 42 weeks), formula‐fed infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Obesity · healthy, full‐term (37 to 42 weeks), formula‐fed infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · healthy, full‐term (37 to 42 weeks), formula‐fed infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · healthy, full‐term (37 to 42 weeks), formula‐fed infants
Standard‐protein formula showed no clear difference in adverse events compared with low‐protein formula (low certainty).
1 finding from 1 review
Stunting · healthy, full‐term (37 to 42 weeks), formula‐fed infants
1 finding from 1 review
Wasting · healthy, full‐term (37 to 42 weeks), formula‐fed infants
1 finding from 1 review
Overweight · healthy, full‐term (37 to 42 weeks), formula‐fed infants
It is very uncertain whether high‐protein formula changes overweight compared with standard‐protein formula (very low certainty).
1 finding from 1 review
Obesity · healthy, full‐term (37 to 42 weeks), formula‐fed infants
It is very uncertain whether high‐protein formula changes obesity compared with standard‐protein formula (very low certainty).
1 finding from 1 review
All‐cause mortality · healthy, full‐term (37 to 42 weeks), formula‐fed infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · healthy, full‐term (37 to 42 weeks), formula‐fed infants
High‐protein formula showed no clear difference in adverse events compared with standard‐protein formula (low certainty).
1 finding from 1 review